Zydus launches Topiramate Extended-Release Capsules

Zydus Lifesciences Limited's (formerly known as Cadila Healthcare Limited) subsidiary Zydus Pharmaceuticals (USA) Inc. (Zydus) has launched Topiramate Extended-Release Capsules. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg (USRLD: Trokendi XR®). Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.

Topiramate Extended-Release capsule is indicated for Epilepsy: initial monotherapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset, primary generalized tonic-clonic seizures, or seizures associated with Lenox-Gastaut Syndrome (LGS). It is also indicated for prophylaxis of migraine in patients 12 years of age and older.

Topiramate Extended-Release capsule had annual sales of USD 488mn in the United States according to IQVIA data (IQVIA MAT Nov. 2022).

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 432.35 as compared to the previous close of Rs. 423.70. The total number of shares traded during the day was 24772 in over 1623 trades.

The stock hit an intraday high of Rs. 433.25 and intraday low of 423.10. The net turnover during the day was Rs. 10648104.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 ZydusPharmaceuticalsUSA Topiramate ExtendedRelease Capsules